Characteristics of patients with gynecologic cancer diagnosed between 2009 and 2017 and female controls, before and after propensity-score matching
| Characteristic | Before matching | Propensity score-matched cohort | ||||
| Cases (n=7446) | Controls (n=3 196 347) | P* | Cases (n=7294) | Controls (n=28 019) | P* | |
| Age at cohort entry, median (IQR)† | 53 (46–58) | 46 (36–54) | <0.0001 | 53 (46–58) | 53 (46–58) | 0.2 |
| Age at cohort entry by group, n (%)† | <0.001 | 0.8 | ||||
| 44 or less | 1613 (21.7) | 1 504 223 (47.0) | 1597 (21.9) | 6263 (22.4) | ||
| 45 to 49 | 1038 (13.9) | 459 818 (14.4) | 1023 (14.0) | 3986 (14.2) | ||
| 50 to 53 | 1176 (15.8) | 377 048 (11.8) | 1155 (15.8) | 4468 (15.9) | ||
| 54 to 57 | 1611 (21.6) | 382 509 (12.0) | 1567 (21.5) | 5940 (21.2) | ||
| 58 to 63 | 2008 (27.0) | 472 749 (14.8) | 1952 (26.8) | 7362 (26.3) | ||
| Health insurance plan type, n (%) | 0.3 | 0.1 | ||||
| HMO | 1130 (15.2) | 481 569 (15.1) | 1070 (14.7) | 3867 (13.8) | ||
| PPO | 4158 (55.8) | 1 763 576 (55.2) | 4116 (56.4) | 16 046 (57.3) | ||
| Other‡ | 2158 (29.0) | 951 202 (29.8) | 2108 (28.9) | 8106 (28.9) | ||
| Region, n (%) | <0.001 | 0.6 | ||||
| Northeast | 1290 (17.3) | 484 037 (15.1) | 1249 (17.1) | 4717 (16.8) | ||
| North central | 1660 (22.3) | 649 676 (20.3) | 1615 (22.1) | 6131 (21.9) | ||
| South | 3056 (41.0) | 1 395 390 (43.7) | 3037 (41.6) | 11 916 (42.5) | ||
| West | 1432 (19.2) | 661 986 (20.7) | 1392 (19.1) | 5254 (18.8) | ||
| Unknown | 8 (0.1) | 5258 (0.2) | 1 (0.0) | 1 (0.0) | ||
| Charlson Comorbidity Index score, n (%) | <0.001 | <0.001 | ||||
| 0 | 6512 (87.5) | 2 981 805 (93.3) | 6485 (88.9) | 25 542 (91.2) | ||
| 1+ | 934 (12.5) | 214 542 (6.7) | 809 (11.1) | 2477 (8.8) | ||
| Index date year, n (%) | <0.001 | <0.001 | ||||
| 2009 | 629 (8.4) | 312 039 (9.8) | 620 (8.5) | 2041 (7.3) | ||
| 2010 | 681 (9.1) | 316 182 (9.9) | 672 (9.2) | 2541 (9.1) | ||
| 2011 | 729 (9.8) | 339 851 (10.6) | 709 (9.7) | 2676 (9.6) | ||
| 2012 | 762 (10.2) | 352 848 (11.0) | 739 (10.1) | 2809 (10.0) | ||
| 2013 | 705 (9.5) | 276 864 (8.7) | 687 (9.4) | 2672 (9.5) | ||
| 2014 | 689 (9.3) | 277 150 (8.7) | 669 (9.2) | 2500 (8.9) | ||
| 2015 | 899 (12.1) | 348 106 (10.9) | 871 (11.9) | 3032 (10.8) | ||
| 2016 | 1216 (16.3) | 464 009 (14.5) | 1198 (16.4) | 4629 (16.5) | ||
| 2017 | 1136 (15.3) | 509 298 (15.9) | 1129 (15.5) | 5119 (18.3) | ||
Propensity-score matching based on all tabulated characteristics.
*P values derived from the Pearson χ2 test or Wilcoxon rank-sum test.
†Age at diagnosis for cancer cohort and age at index date (date of billable encounter with provider) for control cohort.
‡Other health insurance plans include comprehensive, point-of-service, point-of-service with capitation, high-deductible, and exclusive-provider-organization health plans.
HMO, health maintenance organization; PPO, preferred provider organization.